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Abstract
Objective
To investigate predictors for improvement of disease-speciﬁc quality of life (QOL) after deep brain stimulation
(DBS) of the subthalamic nucleus (STN) for Parkinson disease (PD) with early motor complications.
Methods
We performed a secondary analysis of data from the previously published EARLYSTIM study, a prospective
randomized trial comparing STN-DBS (n = 124) to best medical treatment (n = 127) after 2 years follow-up
with disease-speciﬁc QOL (39-item Parkinson’s Disease Questionnaire summary index [PDQ-39-SI]) as the
primary endpoint. Linear regression analyses of the baseline characteristics age, disease duration, duration of
motor complications, and disease severity measured at baseline with the Uniﬁed Parkinson’s Disease Rating
Scale (UPDRS) (UPDRS-III “oﬀ” and “on”medications, UPDRS-IV)were conducted to determine predictors
of change in PDQ-39-SI.
Results
PDQ-39-SI at baseline was correlated to the change in PDQ-39-SI after 24 months in both treatment groups
(p < 0.05). The higher the baseline score (worse QOL) the larger the improvement in QOL after 24 months.
No correlation was found for any of the other baseline characteristics analyzed in either treatment group.
Conclusion
Impaired QOL as subjectively evaluated by the patient is the most important predictor of beneﬁt in
patients with PD and early motor complications, fulﬁlling objective gold standard inclusion criteria for
STN-DBS. Our results prompt systematically including evaluation of disease-speciﬁc QOL when
selecting patients with PD for STN-DBS.
Clinicaltrials.gov identifier
NCT00354133.
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High-frequency deep brain stimulation (DBS) of the sub-
thalamic nucleus (STN) is a powerful treatment in selected
patients with Parkinson disease (PD) and levodopa-induced
motor complications. The beneﬁt of STN-DBS has ﬁrst been
shown in advanced PD with severe motor ﬂuctuations and
dyskinesia1–3 but more recently, improvement of quality of life
(QOL) and motor function have been shown with STN-DBS
at an earlier stage.4–6 The EARLYSTIM study6 addressed STN-
DBS in patients with PD under 61 years of age who had a good
(i.e., ≥50%) response to levodopa but had had motor com-
plications for up to 3 years (mean 1.5 ± 0.8 SD years). In-
tentionally permissive inclusion criteria were chosen that
allowed a rather broad population of patients with PD with
early motor complications to be included. This was decided to
enable recruitment of a large cohort and to build a study
population from which one would be able to draw conclusions
for a clinical population of a reasonably broad range.
This, however, resulted in a study population of patients with
PD with a range from early mild complications to moderately
severe and advancedmotor complications close to those for the
conventional indication for DBS. Therefore, the question came
up whether the beneﬁcial eﬀect of DBS in the EARLYSTIM
cohort was (mainly or only) driven by a subgroup of the entire
population, i.e., the relatively advanced patients. Doubts were
uttered by critics of the study whether patients with milder
motor complications would beneﬁt from DBS. Indeed, it is
possible that the more advanced patients contributed more to
the overall beneﬁcial eﬀect of DBS found in the study than
patients with very mild and early motor complications.
We therefore performed subgroup analyses to understand the
eﬀects of DBS in function of diﬀerent variables prone to be
related to outcome of STN-DBS. In particular, the relative
contributions of age, duration of disease, and severity of dis-
ease to the eﬀect of DBS on QOL were analyzed.
Methods
The EARLYSTIM study5,6 was a prospective randomized
study comparing STN-DBS with best medical treatment
(BMT) to BMT alone over 2 years’ follow-up with QOL
measured with 39-item Parkinson’s Disease Questionnaire
summary index (PDQ-39-SI) as the primary endpoint. The
protocol and statistical plan of the main study are available
at nejm.org/doi/suppl/10.1056/NEJMoa1205158/suppl_
ﬁle/nejmoa1205158_protocol.pdf. Hypotheses of predict-
ing factors for outcome were formulated before secondary
analyses were carried out. Baseline characteristics, including age,
disease duration, duration of motor complications (motor ﬂuc-
tuations and dyskinesia), severity of motor parkinsonian signs
“oﬀ” and “on” medication as measured with the Uniﬁed Par-
kinson’s Disease Rating Scale (UPDRS) motor part (III), se-
verity of motor complications (UPDRS-IV), levodopa response,
and baseline QOL (PDQ-39-SI) were expected to contribute to
the outcome of QOL. To control for contribution of cognition
and mood to the outcome in QOL, the baseline ratings for the
Mattis Dementia Rating Scale (MDRS), the Beck Depression
Inventory (BDI), and the Montgomery-Åsberg Depression
Rating Scale (MÅDRS) were also analyzed as potential pre-
dictors for change on QOL. Univariate linear regression anal-
yses of these baseline characteristics vs the change in QOL
(PDQ-39-SI) were conducted. p Values ≤0.05 were considered
statistically signiﬁcant and no adjustments were made for mul-
tiple comparisons. A multivariate linear regression analysis of
the STN-DBS group was then performed including the factors
with a p < 0.25 in the univariate analysis.
A post hoc subgroup analysis was performed for the correla-
tion of baseline PDQ-39-SI with the change in PDQ-39-SI
over the 2 years using 4 subgroups of baseline PDQ-39-SI
(<15, 15–30, 30–45, >45).
Data availability statement and
protocol standards
The study protocol and statistical plan is available at
nejm.org/doi/suppl/10.1056/NEJMoa1205158/suppl_
ﬁle/nejmoa1205158_protocol.pdf. Datawill not be available
on the web. Researchers can submit proposals for collaborative
studies. The study has been approved by the Kiel and Paris
University ethics committees. The trial is registered at Clin-
icalTrials.gov number, NCT00354133.
Results
The change inQOL over the 2 years correlated with the baseline
value of the PDQ-39-SI in a regressionmodel for each treatment
group (STN-DBS p < 0.001, medical group p < 0.001). How-
ever, this eﬀect was more pronounced among patients who were
treated with STN-DBS than in patients in the medical control
group (p = 0.0262 for interaction) (ﬁgure 1).
If baseline PDQ-39-SI was used to deﬁne categories of
severity of impairment due to PD, patients with very mild
impairment of QOL, i.e., PDQ-39-SI values under 15, as
a group did not beneﬁt from STN-DBS as compared to
Glossary
BDI = Beck Depression Inventory; BMT = best medical treatment; DBS = deep brain stimulation; MÅDRS = Montgomery-
Åsberg Depression Rating Scale; MDRS = Mattis Dementia Rating Scale; PD = Parkinson disease; PDQ-39-SI = 39-item
Parkinson’s Disease Questionnaire summary index; QOL = quality of life; STN = subthalamic nucleus; UPDRS = Uniﬁed
Parkinson’s Disease Rating Scale.
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patients in the control group with best medical treatment
alone. However, in this group, patients with a very favorable
as well as unfavorable outcome in terms of PDQ-39-SI were
found. For the other categories with PDQ-39-SI ratings >15
at baseline, STN-DBS resulted in better QOL than best
medical treatment alone (ﬁgure 2). The change from base-
line to 5, 12, and 24 months for each patient with a change at
each point (n = 241/251) by treatment group is shown in
ﬁgure 3.
The change of QOL over the study duration of 2 years was
independent of age, duration of PD, and duration of motor
complications (motor ﬂuctuations, dyskinesia) at baseline in
a regression model. This was the case when analyzed sepa-
rately by treatment group as well as in a multiple regression
model including allocation to the treatment group.
The change of QOL over the 2 years was also independent
of the severity of parkinsonian motor signs in the condition
Figure 1 Correlation between 39-item Parkinson’s Disease Questionnaire summary index (PDQ-39-SI) at baseline and
change to 24 months
The relation between PDQ-39-SI at baseline and the improvement PDQ-39-SI between baseline and 24months is shown. The correlation ismore pronounced
for the deep brain stimulation (DBS) group than for the best medical treatment (BMT) group.
Figure 2 39-Item Parkinson’s Disease Questionnaire summary index (PDQ-39-SI) by baseline category
Four categories of PDQ-39-SI baseline values were
formed: 0–15, 15–30, 30–45, and >45 points. Higher
values on the PDQ-39 scale mean worse quality of life.
The ordinate indicates the change of PDQ-39-SI over
the 2 years of the EARLYSTIM study period; negative
values mean worsening of quality of life, positive val-
ues mean improvement. BMT = best medical treat-
ment (i.e., control group); DBS = deep brain
stimulation of the subthalamic nucleus plus best
medical treatment; n = number of patients in each
group. *DBS vs BMT statistically significant (adjusted
model-based p values <0.05).
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“oﬀ” and “on” medications as measured with the UPDRS-
III, and independent of the severity of levodopa-induced
complications measured with the UPDRS-IV, as well as
“oﬀ” time at baseline. This was the case when analyzed
separately by treatment group as well as in a multiple
regression model including allocation to the treatment
group.
The levodopa response of the motor score (UPDRS III) at
baseline was not predictive for the change of the QOL
outcome between baseline and 24 months in the DBS-group
or in the BMT control group.
Cognitive assessment at baseline with the MDRS was not
predictive of change in QOL in either treatment group.
Self-assessment of mood using the BDI at baseline did
not predict change of the PDQ-39-SI after 2 years among
patients in the BMT group. However, higher baseline
ratings on the BDI correlated with larger improvement of
QOL among patients with STN-DBS. The same was
Figure 3 Individual 39-item Parkinson’s Disease Questionnaire summary index (PDQ-39-SI) change
Change of quality of life (PDQ-39) depending on the baseline PDQ-39 (B). All data at the 3 visits (5, 12, and 24months) of all patients are shown depending on
the baseline value of the PDQ-39 (left column). The response is highlighted by colors (green, better; red, no change). Patients with higher PDQ-39 values at
baseline show a better improvement.
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observed for mood assessed by the examiner as rated
with the MÅDRS in patients with STN-DBS. On the
other hand, lower ratings on the MÅDRS correlated
with better improvement of the PDQ-39-SI in patients
with BMT.
The multivariate regression model in patients with STN-DBS
included 4 baseline factors with p < 0.25 in the univariate
analysis: PDQ-39-SI (p < 0.0001), BDI (p < 0.001), MÅDRS
(p = 0.018), and UPDRS-III “oﬀ” medication (p = 0.216).
Only the PDQ-39-SI remained signiﬁcant (p < 0.0001) as
a baseline predictor for change in QOL in the multivariate
model.
Discussion
The EARLYSTIM cohort was intended to broadly represent
the group of relatively young patients with PD and early
motor complications as seen in daily practice. In such a co-
hort, the potential for improvement may be more modest
than in more advanced PD and patients’ expectations are high
for STN-DBS. Weighing surgery against BMT, knowledge
about predictive factors for the improvement of QOL with
either treatment is important. Moreover, in view of negative
results of STN-DBS in patients with PD before the onset of
motor complications,7 STN-DBS at a very early stage has
been challenged, as the relative contributions of age, disease
duration, and duration of presence of motor complications
have so far not been disentangled.8
QOL at baseline was positively correlated with the im-
provement of the PDQ-39-SI. This was true for both treat-
ment groups, i.e., patients with worse QOL at baseline
improved more over the 2 years’ study period. This was,
however, very much more pronounced among patients with
STN-DBS than with BMT alone. Baseline impairment of
QOL is therefore a reasonable aspect to consider for the
decision to treat with STN-DBS. We wondered if there was
a ﬂoor eﬀect for the beneﬁt from STN-DBS with a minimal
PD-related suﬀering required to have a potential advantage
from the intervention. Among patients with PDQ-39-SI
ratings under 15, there was as a group no diﬀerence for the
outcome in QOL between the treatment groups, and
patients with STN-DBS even tended to have worse average
outcomes. However, this post hoc secondary analysis must
be taken with reserve, especially since the subgroup with
PDQ-39-SI ratings under 15 was very small and some indi-
viduals in this group had an excellent improvement of QOL
with STN-DBS and would wrongly have been barred from
a beneﬁcial treatment if a strict cutoﬀ level for the indication
of STN-DBS had been applied. In patients with very low
baseline ratings on the PDQ-39-SI, the natural progression
of impairment of QOL may outweigh the improvement
achieved by STN-DBS. On the other hand, some patients
with very modest impairment of their QOL seem to have less
to gain from STN-DBS. If they choose to undergo neuro-
surgery, they may do it for the wrong reasons and have
expectations that are unrealistic. Therefore they may end up
disappointed with the result and show worse ratings on the
PDQ-39-SI. Especially thorough assessment of the reasons
to undergo neurosurgery and the expectations from STN-
DBS are therefore needed if the impairment of QOL is very
modest. For all other categories with higher PDQ-39-SI at
baseline, STN-DBS resulted in improved QOL as compared
to best medical treatment alone.
In contrast to the strong prediction of improvement of QOL
by baseline PDQ-39-SI ratings, the change of QOL after 2
years is independent from age, disease duration, duration of
motor complications, and severity of motor signs and motor
complications at baseline. This ﬁnding diﬀers from the ob-
servation in more advanced PD in patients with a higher age
after 5–6 months where baseline cumulative daily “oﬀ” time
was a predictor for improvement of the PDQ-39-SI9 and
younger age was associated with better improvement of the
PDQ-8.10 This diﬀerence could be partly related to the longer
observation period of 2 years, the diﬀerent patient proﬁle
(younger age, shorter disease duration at surgery) in the
EARLYSTIM study, and to a lower variance as a result of the
narrower inclusion criteria.
The discrepancy between health-related QOL and motor
disease severity at baseline as predictors for the outcome of
QOL can be explained by the individual amount of suﬀering
attributed to a given motor impairment. Objective motor
improvement does not equal subjective improvement of
overall disease-speciﬁc QOL.11 Moreover, the PDQ-39 not
only assesses motor aspects of PD, but aﬀective, behavioral,
cognitive, nonmotor, and psychosocial issues are also weighed
with this instrument. It is known that motor signs are not the
most important determinant of QOL in patients with
PD.12–14 Indeed, nonmotor aspects also strongly inﬂuence the
PDQ-39-SI15 and thus contribute decisively to the changes of
QOL after STN-DBS. This is likely the reason why the L-dopa
response of the UPDRS motor score at baseline is predictive
for the motor outcome16,17 but not necessarily for the QOL
outcome after 2 years.9,18,19 It has been shown that patients
without dementia with borderline preoperative cognitive
scores improve less in QOL than those with better cognitive
ratings.20 However, only patients without dementia without
severe depression were included in the EARLYSTIM study. It
is therefore not surprising that baseline assessments of cog-
nition (MDRS) and mood (BDI, MÅDRS) were not pre-
dictive for outcome. The association of higher ratings on the
depression scales with better improvement of QOL among
STN-DBS patients may indicate that these patients have
a potential for nonmotor improvement to gain from surgery.
However, the association was present only in univariate
analyses and lost in themultivariate model, in which the PDQ-
39-SI baseline score dominated all other factors.
An important limitation of our ﬁndings regarding general-
ization is the highly selected patient population. Indeed, the
EARLYSTIM cohort consisted of young patients under 61
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with a levodopa response of at least 50% as an inclusion
criterion. STN-DBS has been established as a treatment for
motor symptoms in advanced PD.1,21–24 Importantly, the
response of motor parkinsonian signs to levodopa is an
established predictor of the motor outcome of STN-DBS.16,25
Parkinsonism that does not respond to L-dopa will not beneﬁt
from STN-DBS.26 In other words, it is not the severity of the
motor signs that predicts motor outcome, but their response
to L-dopa. In the present study, levodopa response at baseline
was not a predictor of improvement in QOL. Part of the expla-
nation may be related to the fact that the same objective motor
sign will not lead to the same subjective suﬀering, and in the same
way improvement of motor symptoms that do not bother a pa-
tient will not lead to improvement inQOL, which by deﬁnition is
subjective. A ceiling eﬀect may also partly explain that no such
association was found among our patients with STN-DBS, given
the fact that levodopa response of at least 50% was deﬁned as an
inclusion criterion and that the operated patients in the EAR-
LYSTIM study had an excellent average baseline levodopa re-
sponse of 63.5% ± 16.2%. Therefore, poor QOL in patients with
PD in the absence of L-dopa-responsive motor symptoms should
not be regarded as an indication for surgery.
The relation between age, disease duration, and outcome may
be diﬀerent in older patients and in patients with a less pro-
nounced response to levodopa. Better outcome of STN-DBS
has been suggested among younger patients with shorter
disease duration,25 and outcome among older patients has
been reported as unfavorable.27 However, these patients were
operated at a later stage for severe advanced PD. Our data
cannot answer the question whether STN-DBS at an earlier
stage will remain advantageous over BMT beyond the 2 years
of the duration of the EARLYSTIM study. Uncontrolled open
long-term observations on patients with STN-DBS, however,
show beneﬁts that last up to a decade.28
The lack of correlations of age, disease duration, and disease
severity with the change of QOL after STN-DBS leaves only
baseline ratings of the PDQ-39-SI as a predictor for change of
QOL. All patient groups above 15 points of PDQ-39-SI at
baseline have on average a clinically meaningful improvement
of their QOL (ﬁgure 2), which has been estimated to be ≥1.6
points.29 The majority of these patients is in the range of PDQ-
39-SI >15 (n = 114).We therefore consider it very unlikely that
the overall favorable outcome of STN-DBS in the EAR-
LYSTIM study has been driven by only a subgroup of patients
corresponding to the traditional indication with severe long-
standing advanced complicated PD. The major and decisive
explanation of the improvement of QOL comes from STN-
DBS, i.e., the treatment itself across a broad range of patient age
and clinical proﬁles within the EARLYSTIM inclusion criteria.
STN-DBS improves QOL in patients with PD and early
motor complications who fulﬁl the EARLYSTIM inclusion
criteria independently of age, disease duration, and disease
severity. The subjective individual suﬀering as measured with
the PDQ-39-SI should be taken into account as a predictive
factor for outcome when selecting patients with early motor
complications for STN-DBS.
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